5th Annual Vivian Pinn Symposium:
Integrating Sex and Gender into Biomedical Research as a Path for Better Science and Innovation
The Office of Research on Women’s Health (ORWH) is thrilled to host the 5th Annual Vivian Pinn Symposium in partnership with the Foundation for the National Institutes of Health (FNIH). In line with ORWH’s mission of putting science to work for the health of women, this event serves as a forum for experts across sectors to communicate and collaborate for the advancement of women’s health.
This year’s event will focus on illustrating the scientific, societal, and economic opportunities of integrating sex and gender into biomedical research and the power of working together. Sex-and gender-aware research is critical for rigorous science, maximizing returns on research investment, and advancing women’s health. However, despite progress made, consideration of sex and gender influences is inconsistently applied across the biomedical ecosystem, highlighting a need for greater integration.
This event will feature a series of panels and breakout sessions with experts from across diverse sectors of academia, industry, non-profits, private funding, and government to generate discussion of system-wide solutions—driving progress towards a healthier future for everyone.
1) Create bridges and capacity to work bi-directionally across silos within the scientific enterprise to build a resilient, interconnected network that includes federal and private funders of research, industry and business, journal editors and publishers, professional societies, scientific and health organizations, healthcare providers, researchers, academic institutions, policymakers, and the public.
2) Develop strategies to achieve the integration of sex and gender considerations throughout the biomedical research enterprise.
3) Characterize issues related to the health of women and explore women’s health research, along with public health opportunities from a multidimensional perspective to advance the integration of sex and gender considerations via trans-sector approaches and partnerships.
Arthur P. Arnold (AB, Grinnell College; PhD, The Rockefeller University) studies mechanisms causing sex differences in physiology and disease. His research has included the discovery of large structural sexual dimorphisms in the CNS, development of several animal models for studying sex differences, and studies of mechanisms by which sex-biasing factors operate, including sex chromosome effects. Dr. Arnold is Distinguished Research Professor in the Department of Integrative Biology & Physiology at UCLA, and a fellow of the AAAS and the John Simon Guggenheim Memorial Foundation. Previous positions include departmental Chair, Associate Director of the UCLA Brain Research Institute, Chair of the UCLA interdepartmental PhD and undergraduate programs for neuroscience, founding President of the Society of Behavioral Neuroendocrinology, and founding Editor-in-Chief of Biology of Sex Differences.
Thomas Babor is a Professor and former Chairman in the Department of Public Health Sciences, University of Connecticut School of Medicine, USA. His academic training is in social psychology, addiction science and psychiatric epidemiology. His research interests include screening, diagnosis, early intervention, and treatment evaluation, as well as alcohol and drug policy. He is Editor-in-Chief of the Journal of Studies on Alcohol and Drugs. He is co-chair of the Gender Policy Committee of the European Association of Science Editors.
Elizabeth Bailey serves as the Managing Director of Rhia Ventures' RH Capital, an impact venture fund investing in transformative innovation for women's health. She has over 15 years of experience in venture capital and supporting early-stage health companies. As a Partner at Commons Capital, one of the first impact investment funds, Elizabeth managed the healthcare and education portfolios, which included Claros Diagnostics (acquired by OPKO), CodeRyte (acquired by 3M), HistoRx (acquired by Genoptix), Medical Metrx Solutions (acquired by AIG), TelaDoc (IPO: TDOC) and Apex Learning (acquired by Education Growth Partners). Elizabeth also served as the Founding DIrector for the Consortium for Affordable Medical Technologies (CAMTech) at Mass General Hospital, where she built a global program to accelerate medtech innovation and catalyze new health startups. She earned a Master's in Public Policy from Harvard's Kennedy School of Government and a BA from Brown University. Throughout her career, Elizabeth has been a strong advocate for the power of business to drive social change
Gilda A. Barabino is President of Olin College of Engineering. She previously served as Daniel and Frances Berg Professor and Dean at The City College of New York’s (CCNY) Grove School of Engineering. Prior to joining CCNY, she was Associate Chair for Graduate Studies and Professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory. At Georgia Tech she also served as the inaugural Vice Provost for Academic Diversity. Prior to Georgia Tech and Emory, she rose to the rank of Professor of Chemical Engineering and was Vice Provost for Undergraduate Education at Northeastern University. She is a noted investigator in the areas of sickle cell disease, cellular and tissue engineering, and the role of race/ethnicity and gender in science and engineering. Dr. Barabino is a member of the National Academy of Engineering and the National Academy of Medicine, president-elect of the American Association for the Advancement of Science (AAAS), the American Institute of Chemical Engineers (AIChE), the American Institute for Medical and Biological Engineering (AIMBE) and the Biomedical Engineering Society (BMES). Dr. Barabino serves on the Scientific Advisory Board of the Chan Zuckerberg Biohub. She is Past-President of BMES and Past- President of AIMBE. She has received an honorary degree from Xavier University of Louisiana, the Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring, AIChE’s Award for Service to Society, and AIMBE’s Pierre Galetti Award. Dr. Barabino is a member of the National Science Foundation’s (NSF) Advisory Committee for Engineering, the congressionally mandated Committee on Equal Opportunities in Science and Engineering, the AAAS Committee on Science, Engineering and Public Policy, and the incoming chair of the National Academies Committee on Women in Science, Engineering, and Medicine. She consults nationally and internationally on STEM education and research, diversity in higher education, policy, faculty and workforce development. She received a B.S. from Xavier University of Louisiana and a Ph.D. from Rice University.
Faz K. Bashi, MD, has a research background in Immunology and Virology at UCSF. He is an active member of Life Science Angel's (LSA) in Silicon Valley. He is also Lead Venture Investor with Portfolia's FemTech Fund I and II, focused on female health and wellness. He is very active in the Animal Health space, and is Pres/CEO at Anubis Bio; an all-natural Microbiome-Cleanser (TM) food-tech platform with first product scaling in revenue, called DoggyStat (www.doggystat.com). He is Advisor to One Health Group (www.onehealthgroup.com) with 72 issued patents providing non-contact, highly accurate, medical-grade remote-monitoring animal health data !
He served a 3-year term as Board Member of the Angel Capital Association (ACA) where he continues to be Chair of the ACA's Life Sciences Syndication group. He is active with UCSF’s Entrepreneurship Startup 101, external advisory board member for UCSF's CTSI and Johns Hopkins' CBID (https://cbid.bme.jhu.edu/), and Advisor to Springboard Enterprises (www.sb.co) Life Sciences Council.
He volunteers his time with Peninsula Bridge program to help the underserved kids of East Palo Alto get inspired about their futures via education. He is committed to helping find treatments for Tinnitus, Autism, Lupus, and Vascular diseases. He completed several triathlons with Team-In-Training to raise funds for the Leukemia and Lymphoma Society.
Mila Becker, Esq., Chief Policy Officer, Endocrine Society Mila oversees the Government & Public Affairs Department, which manages the Society’s public policy agenda and advocacy efforts. Her work includes developing strategies to improve policies that will impact research funding and policies, clinician payment, and quality of care. She has worked extensively on women’s health and women’s health research issues and on global advocacy related to endocrine disrupting chemicals. She also serves as liaison to the Clinical Affairs, Research Affairs, and Advocacy & Public Outreach Core Committees and is a Board member of the Coalition for Health Funding. For the last 20 years, Mila has worked in government relations for non-profit health related organizations. Prior to joining the Endocrine Society in July 2013, she spent ten years at the American Society of Hematology as the Senior Director for Government Relations, Practice, & Scientific Affairs. Before that, she worked as a senior lobbyist for AARP where she was responsible for prescription drug and other high priority health issues, and she was Director of Public Policy for Partnership for Prevention, a coalition dedicated to disease prevention and health promotion. She holds a BA in political science from Northwestern University and a JD from Georgetown University Law School.
May Berenbaum Ph.D. has been on the faculty of the Department of Entomology at the University of Illinois at Urbana-Champaign since 1980, serving as head since 1992 and as Swanlund Chair of Entomology since 1996. Her research, which has produced more than 300 publications, focuses on mechanisms underlying interactions between insects and plants and on incorporating ecological principles into sustainable management practices, testifying twice before Congress on issues relating to pollinator decline. Devoted to teaching and fostering scientific literacy, she has authored numerous magazine articles and six books about insects for the general public. With respect to issues of diversity, equity, and inclusion, at UIUC during her long tenure as department head she has worked to increase the proportion of faculty from underrepresented minority groups to its current level of 51% (including the first two black female faculty members in the School of Integrative Biology). As a member of National Academy of Sciences, she has served as a member of the NASEM Report Review Committee and reviewed several reports on the status of women in science, as a member of the NASEM Committee on Women in Science, Engineering, and Medicine, and as a member of the study committee authoring the 2020 report Promising Practices for Addressing the Underrepresentation of Women in Science, Engineering, and Medicine: Opening Doors. As Editor-in-Chief of the Proceedings of the National Academy of Sciences, she has authored editorials on race and gender issues in science and is working to increase participation of women and other underrepresented groups on the Editorial Board.
Chloe E. Bird, Ph.D., FAAAS, FAAHB, is a senior sociologist at RAND, where she studies women's health and determinants of differences in men’s and women’s health and health care. Her current work examines the return on investment of increasing funding for research on the health of women and assesses gaps in women’s health care and ways to improve and integrate women’s reproductive health care into their care across the life course to reduce cardiovascular risk, improve outcomes, and address racial disparities. Her recent projects include a study assessing gender disparities in quality of care among Medicare Advantage beneficiaries. In her book Gender and Health: The Effects of Constrained Choice and Social Policies (Cambridge University Press, 2008), she and coauthor Patricia P. Rieker explore how policymakers and other stakeholders shape individuals’ opportunities to pursue a healthy life. They emphasize the need for research that informs stakeholders' decisions in order to improve women's health and reduce disparities. Dr. Bird has served as a senior advisor in the National Institutes of Health’s Office for Research on Women’s Health and as editor-in-chief of the journal Women's Health Issues, where she is now associate editor. She received the 2020 William Foote Whyte career award from American Sociological Association Section on Sociological Practice and Public Sociology for her work on the health of women, and a 2015 Leadership Award, California Department of Managed Health Care “for improving women’s cardiovascular outcomes and reducing gender disparities”. Dr. Bird is working to build a donor-funded Women's Health Research and Policy Center at RAND. She is a Fellow of the American Association for the Advancement of Science and the American Academy of Health Behavior, and a member of Women of Impact in Healthcare. She earned her Ph.D. and M.A. in sociology from the University of Illinois at Urbana-Champaign.
Heather Bowerman is the founder and CEO of DotLab, a molecular diagnostics company in women’s health. Bowerman has been recognized as a TR-35 Global Innovator by the MIT Technology Review, a World Technology Award Finalist for Health & Medicine, and as one of the 100 Most Intriguing Entrepreneurs by Goldman Sachs. She was previously a management consultant at McKinsey & Company in healthcare and technology, an associate in the Obama White House’s Office of Science & Technology Policy, and Harvard’s nanotechnology teaching fellow. She is a graduate of the UC Berkeley College of Engineering and Harvard University. Bowerman founded DotLab in 2016 because one of the world’s most prevalent, irreversibly debilitating diseases—that happens to only affect females—lacks sufficient tools for diagnosis, leaving millions undiagnosed or with a significant delay to diagnosis. DotLab has launched the “EMPOWER” study across the US, one of the largest-ever efforts to evaluate a non-invasive diagnostic tool for endometriosis and the first multi-center, prospective, cohort clinical diagnostic study of its kind. The biology of endometriosis is complicated and poorly understood, and a study like EMPOWER is necessary to bring diagnostic tools to market. Historically, studies of this magnitude have been lacking because women’s health is an underserved market, today representing less than 5% of healthcare research spend. The EMPOWER Study represents a significant stride for endometriosis and women’s health. DotLab has been named as an “Amazing Medical Breakthrough” by Reader’s Digest and as one of the “Fierce 15” companies by FierceMedTech.
Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health for Verily and Google Health. Prior to this Dr. Califf was the vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke’s center for health data science; and the Donald F. Fortin, MD, Professor of Cardiology. He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017. A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine. Dr. Califf was the founding director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.
Ana Mari Cauce is the 33rd president of the University of Washington where she has been a member of the faculty since 1986. A graduate of the University of Miami and Yale University, she is a noted scholar on risk and resilience among adolescents. A member of the American Academy of Arts and Sciences, she has received numerous awards for her research as well as the University’s Distinguished Teaching Award. Before becoming president in 2015, she served as Director of Clinical Training in Psychology, as chair of the Departments of American Ethnic Studies and Psychology, as dean of the College of Arts and Sciences and as Provost. In 2008, she played a key role in establishing the Husky Promise, a program that has helped more than 40,000 low-income students attend the UW. Since becoming president, Cauce has put a spotlight on the UW’s work in Population Health across the University, launched the University’s Race & Equity Initiative and been a champion for ensuring the UW and public higher education across the country remain accessible and affordable for all students. She is also a strong advocate for women and underrepresented Black, Indigenous, Latinx and other people of color to pursue careers in science, technology, engineering, mathematics, business and health fields. As president, and throughout her tenure, she has worked to advance the University’s mission of serving the public good by focusing on the UW’s impact on the lives of the people in Washington and throughout the world.
Anne Claiborne is a Manager in the Science in Society Program at the Chan Zuckerberg Initiative. In this role she develops and manages opportunities to enable community, civic, and policy engagement by scientists and to foster an equitable, inclusive, and responsive scientific ecosystem. She also advises on the strategic direction and priorities of the Science in Society program and coordinates diversity, equity, and inclusion efforts across CZI’s Science initiative. Prior to joining CZI in March 2018, she spent eight years as a Senior Program Officer at the National Academies of Sciences, Engineering, and Medicine, where she focused on health sciences policy and ethics relating to clinical research and therapeutics discovery. At the National Academies, she was the responsible staff officer for, among other programs, the Forum on Drug Discovery, Development, and Translation (roundtable director); Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations (study director); Research & Development of Medical Products for Epidemic Response (Hong Kong workshop director); and Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk (senior advisor and team lead). Before the National Academies, she was a health care lawyer in private practice at an international law firm. Over the course of her career, she has advised and managed complex, high-stakes health regulatory and biomedical research policy programs across diverse areas, including innovative and emerging bioscience, patient-driven research, clinical and translational science, novel biotechnology development collaborations, epidemic disease, and global research and public health capacity-building. She received her A.B. with distinction from Stanford University; her juris doctorate cum laude from Harvard Law School, where she was an editor of the Harvard Law Review; and her MPH from Johns Hopkins Bloomberg School of Public Health.
Janine Austin Clayton, M.D., FARVO, was appointed Associate Director for Research on Women’s Health and Director of the Office of Research on Women’s Health at the National Institutes of Health (NIH) in 2012. Dr. Clayton has strengthened NIH support for research on diseases, disorders, and conditions that affect women. She is the architect of the NIH policy requiring scientists to consider sex as a biological variable across the research spectrum, a part of NIH’s initiative to enhance reproducibility, rigor, and transparency. As co-chair of the NIH Working Group on Women in Biomedical Careers with NIH Director Dr. Francis Collins, Dr. Clayton also leads NIH’s efforts to advance women in science careers. In 2021, Dr. Clayton was elected to the Board of Directors of the American Association for the Advancement of Science (AAAS). Dr. Clayton was previously the Deputy Clinical Director of the National Eye Institute (NEI). A board-certified ophthalmologist, Dr. Clayton’s research interests include autoimmune ocular diseases and the role of sex and gender in health and disease. Dr. Clayton has a particular interest in ocular surface disease and discovered a novel form of disease associated with premature ovarian insufficiency that affects young women, setting the stage for her commitment to rigorous, thoughtful exploration of the role of sex and gender in health and disease. She is the author of more than 120 scientific publications, journal articles, and book chapters. Her clinical research has ranged from randomized controlled trials of novel therapies for immune-mediated ocular diseases to studies on the development of digital imaging techniques for the anterior segment. Dr. Clayton, a native Washingtonian, received her undergraduate degree with honors from Johns Hopkins University and her medical degree from Howard University College of Medicine. She completed a residency in ophthalmology at the Medical College of Virginia. Dr. Clayton completed fellowship training in cornea and external disease at the Wilmer Eye Institute at Johns Hopkins Hospital and in uveitis and ocular immunology at NEI. Dr. Clayton has received several awards and has been recognized as a leader by her peers. She received the Senior Achievement Award from the Board of Trustees of the American Academy of Ophthalmology in 2008, was selected as a 2010 Silver Fellow by the Association for Research in Vision and Ophthalmology, and won the European Uveitis Patient Interest Association Clinical Uveitis Research Award in 2010. In 2015, she was awarded the American Medical Women’s Association Lila A. Wallis Women’s Health Award and the Wenger Award for Excellence in Public Service. Dr. Clayton was granted the Bernadine Healy Award for Visionary Leadership in Women’s Health in 2016. She was also selected as an honoree for the Woman’s Day Red Dress Awards and the American Medical Association’s Dr. Nathan Davis Awards for Outstanding Government Service in 2017.
Francis S. Collins, M.D., Ph.D., was appointed the 16th Director of the National Institutes of Health (NIH) by President Barack Obama and confirmed by the Senate. He was sworn in on August 17, 2009. On June 6, 2017, President Donald Trump announced his selection of Dr. Collins to continue to serve as the NIH Director. In this role, Dr. Collins oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research.
Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at NIH from 1993-2008.
Before coming to NIH, Dr. Collins was a Howard Hughes Medical Institute investigator at the University of Michigan. He is an elected member of the National Academy of Medicine and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in November 2007, and received the National Medal of Science in 2009. In 2020, he was elected as a Foreign Member of the Royal Society (UK) and was also named the 50th winner of the Templeton Prize, which celebrates scientific and spiritual curiosity.
Shaheen Contractor is an Environmental, Social and Governance (ESG) Research Analyst for Bloomberg Intelligence, a platform that provides research on industries, companies, government, litigation and the economy, available on the Bloomberg Professional Services at BI<GO>. Her research efforts include analyzing the performance of ESG Indexes and funds, material ESG risks and opportunities, the impacts from a low carbon transition, and company performance on the UN Sustainable Development Goals. Mrs. Contractor has a Master of Science degree in Sustainability Management from Columbia University and a Bachelor of Business Administration (BBA) degree from Symbiosis International University.
Nakela L. Cook, MD, MPH, is Executive Director at the Patient-Centered Outcomes Research Institute (PCORI). She is a cardiologist and health services researcher with a distinguished career leading key scientific initiatives engaging patients, clinicians, and other healthcare stakeholders at one of the nation’s largest public health research funders.
Cook leads PCORI’s research, dissemination and implementation, and engagement work as the organization enters its second decade of service to the nation. She also provides strategic and day-to-day oversight of ongoing programs as well as new initiatives designed to create a healthcare system that is more efficient, effective, and patient centered.
Prior to her current role, Cook served as Senior Scientific Officer and Chief of Staff at the National Heart, Lung, and Blood Institute (NHLBI), the third largest institute of the National Institutes of Health, with a staff of 1,000 and an annual budget of over $3 billion. There she spearheaded the development and implementation of NHLBI’s strategic plan and initiatives in precision medicine, data science, sickle cell disease, and women’s health with meaningful engagement of stakeholder groups.
Preceding her position as Chief of Staff, Cook was a Clinical Medical Officer in NHLBI’s Division of Cardiovascular Sciences and an attending cardiologist at the Washington Hospital Center in Washington, DC. She has a bachelor of science degree in materials science and engineering from the University of Alabama at Birmingham; earned her medical degree and master of public health in health care policy and management from Harvard Medical School and Harvard School of Public Health, respectively; and completed her clinical training at Massachusetts General Hospital in Boston. Cook is also an alumna of the Commonwealth Fund/Harvard University Fellowship in Minority Health Policy.
Throughout her career, Cook has worked to enhance diversity and equity in research and care delivery and been a leader in efforts to reduce disparities in health access and outcomes. She has received numerous awards for her excellence in clinical teaching and mentorship as well as her leadership of complex scientific initiatives and programs.
Sara is one of the most influential networkers and connectors in the life sciences industry. As the CEO & Founder of Demy-Colton, a leading life sciences events organizer, she brings more than 22 years of experience launching, developing, and shaping high-profile investor and business development conferences in the healthcare industry. In 2008, Sara founded Demy-Colton, a company dedicated to facilitating growth in life sciences and digital medicine, through the creation of compelling industry conferences and virtual events. She is committed to fostering the support and advancement of entrepreneurs and companies that are focused on bringing innovative new therapies to improve patient lives and care. Sara is a fierce advocate for diversity in all forms and has made a commitment to fostering inclusion in all Demy-Colton events, both in-person and virtual. As one of the founders of Biotech Showcase, she led the movement on calling out “manels,” and made a commitment to ensure gender diversity on all panels, at all events. Prior to founding Demy-Colton, Sara was Vice President for Business Development and Investor Relations at the Biotechnology Innovation Organization (BIO). During her tenure, she led the launch of the BIO CEO & Investor Conference, BIO Investor Forum, BIO Asia, regional investor forums, the Business Forum at BIO’s annual meeting. She expanded BIO-Europe, helped launch BioEurope Spring, and BioEquity, and developed the partnering system that is now an important component of all biopharma business development meetings. Sara was also Director for Foreign Investment at the Empire State Development Corporation, which has a mission of making New York a location of choice for international companies. One of her clients was Beecham Pharmaceuticals, now a part of GSK, which was looking to build a 600-person ethical research facility. It was through her work with Beecham that she was introduced to the then nascent biopharma industry and ultimately, BIO. Sara holds a BA in International Relations from the University at Albany.
Josh Denny is the Chief Executive Officer of the National Institutes of Health’s All of Us Research Program. He has been involved in All of Us from its inception, first as a member of the Advisory Committee to the (NIH) Director Precision Medicine Initiative Working Group, which developed the program’s initial scientific blueprint. He led the program’s initial prototyping project and served as the principal investigator for the All of Us Data and Research Center. As a physician scientist, Josh is deeply committed to improving patient care through the advancement of precision medicine. Before joining the NIH, Josh was a Professor of Biomedical Informatics and Medicine, Director of the Center for Precision Medicine, and Vice President for Personalized Medicine at Vanderbilt University Medical Center. In his roles at VUMC, he was both a practicing internist and a researcher. His research interests include use of electronic health records (EHRs) and genomics to better understand disease and drug response. He also led efforts implementing precision medicine to improve patient outcomes. Josh was a leader in the development of phenome‐wide association studies (PheWAS) and phenotype risk scores. He served as PI for Vanderbilt sites in the Electronic Medical Records and Genomics (eMERGE) Network, Pharmacogenomics Research Network (PGRN), and the Implementing Genomics into Practice (IGNITE) Network. He is an elected member of the National Academy of Medicine, the American Society for Clinical Investigation, and the American College of Medical Informatics.
Jennifer Duck serves as Vice President of Public Affairs for Novo Nordisk Inc. Prior to joining Novo, Jennifer served as Staff Director and Chief Counsel of the Senate Judiciary Committee for the minority and as Chief of Staff for Senator Dianne Feinstein of California. Jennifer spent several years working at Pfizer, Inc. as Vice President of Policy, External Affairs, and Communications. Her previous government experience included serving as Staff Director and Chief Counsel on the Subcommittee of Terrorism, Technology and Homeland Security of the Senate Judiciary Committee; as well as counsel to Democratic Leader Tom Daschle; counsel for Senator Ted Kennedy on the Senate Health, Education, Labor and Pensions Committee; and, as a Senior Policy Advisor for the Senate Democratic Policy Committee. Jennifer’s executive branch and state and local government experiences include time in the Clinton Administration at the Department of Labor’s Office of Intergovernmental Affairs where she managed outreach to state and local officials as well as with Congressional Affairs. Jennifer worked on the Obama Presidential Transition with the teams for the Department of Health and Human Services, the Office of Management and Budget, the CIA, and the Department of Labor. Jennifer also worked for State Senator Bill Luther and for Faribault-Goodhue-Wabasha counties in MN. Jennifer earned her law degree from Emory University in Atlanta, Georgia and is a member of the Bar in the State of Georgia. She earned her Bachelor’s degree from St. Olaf College in Northfield, Minnesota and studied in Brazil, Japan, Taiwan, China, Hong Kong and Thailand.
Holly J. Falk-Krzesinski, PhD, is the Vice President, Research Intelligence with the Global Strategic Networks team at Elsevier. Her key role is giving voice to research leaders at universities, funders, and science policy organizations to help Elsevier deliver the most impactful research information solutions to support research globally. Dr. Falk-Krzesinski serves as Co-chair of Elsevier’s Gender Equity Taskforce and is co-author on Elsevier’s two global gender analytics reports. Dr. Falk-Krzesinski is actively involved in the organization’s executive-level Inclusion & Diversity (I&D) efforts, advocating for greater gender diversity among STEMM leadership, and promoting sex and gender-based analysis (e.g., NIH SABV policy) in published research studies. Most recently, she has been leading Elsevier’s efforts to consistently collect self-reported Gender (and Race & Ethnicity) Identity data across platforms for actionable insight regarding scholarly communications and publishing processes.
Dr. Fauci was appointed Director of NIAID in 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis and malaria as well as emerging diseases such as Ebola and Zika. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies. The NIAID budget for fiscal year 2021 is an estimated $6.1 billion. Dr. Fauci has advised seven Presidents on HIV/AIDS and many other domestic and global health issues. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), a program that has saved millions of lives throughout the developing world.
Maria C. Freire, PhD is the President and Executive Director and member of the Board of Directors of the Foundation for the National Institutes of Health (FNIH). The FNIH has a substantive portfolio of innovative research and clinical programs that advance biomedical science. Prior to FNIH, from 2008 to 2012, she was President of the Albert and Mary Lasker Foundation, where she established programmatic initiatives that expanded the brand and reach of the foundation. From 2001 to 2008, she served as President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit organization that develops drugs to fight tuberculosis, and from 1995 to 2001, she directed the Office of Technology Transfer at the NIH.
Dr. Freire obtained her BS degree at the Universidad Peruana Cayetano Heredia in Lima, Peru, and her PhD in Biophysics from the University of Virginia. She completed postgraduate work in Immunology and Virology at the University of Virginia and the University of Tennessee, respectively, and at the John F. Kennedy School of Government, Harvard University. She is widely recognized as an expert in technology commercialization and has a wide range of experience in the public and private biomedical sectors.
Dr. Freire is active on national and international boards and committees. She is the Chair of the Business Advisory Board of the Institute for Research in Biomedicine in Barcelona, Spain; is a Director of Alexandria Real Estate Equities, Inc.; is on the Board of Directors for Exelixis,Inc.; has served as a member of the Commission on a Global Health Risk Framework for the Future of the National Academy of Medicine and the Executive Committee of the United Nations’ Sustainable Development Solutions Network; and was a member of the UN Secretary General’s High-Level Panel on Access to Medicines. She is a member of the National Academy of Medicine and the Council on Foreign Relations.
Dr. Freire is the recipient of numerous awards, including the 2019 “Executive of the Year” Award from NonProfit PRO, the 2017 Gold Stevie Award for “Woman of the Year”, the 2017 Washington Business Journal’s Women Who Mean Business Award, the HHS Secretary’s Award for Distinguished Service, the Arthur S. Flemming Award and the Bayh-Dole Award.
Jennifer Friel Goldstein is the Managing Partner for Life Science & Healthcare at SVB Capital and a founding member of Venture Forward, a non-profit that provides resources and education towards developing a diverse, equitable, and inclusive venture ecosystem. She is also an advisory board member of Springboard Enterprises and the Women’s Health Innovation Coalition. A bioengineer by training, Jennifer is passionate about the role that venture investing can bring to discovery in the fields of health care and life sciences. She is currently leading SVB Capital’s Life Science & Healthcare investment team and helping develop the bank’s first life science direct investment fund for institutional Limited Partners. Jennifer has more than 20 years of experience in the venture and startup market segments, including leading and building several teams over the past 8 years at Silicon Valley Bank. Prior to that, she was a director on Pfizer's Venture Capital team, where she helped lead or co-lead investments into several life sciences companies, led fund-of-fund investment decisions, and independently managed Pfizer’s $250 million private equity portfolio. Jennifer has also served as a consultant on private equity deals across Europe while at Bain & Company and has held operational and research roles at Chiron, Genelabs, and Genencor. Jennifer graduated magna cum laude with a BSE in Bioengineering and a Master's of Biotechnology from the University of Pennsylvania. She holds an MBA from the Wharton School, where she was named a Joseph Wharton Fellow. She also serves as an independent director at Alexandria Real Estate Equities, Inc. Jennifer lives in the Bay Area with her husband and their twin children.
Hilary Gammill, MD is the Deputy Director for Maternal Health and Discovery on the Maternal, Newborn, and Child Health - Discovery & Tools team in the Global Health division at the Bill & Melinda Gates foundation. Her specific areas of focus on the team include understanding drivers of adverse pregnancy outcomes, developing interventions to prevent and treat obstetric complications, and developing devices to optimize care and inform pregnancy risk stratification, all focused on low- and middle-income country contexts. A maternal-fetal medicine physician-scientist by training, Dr. Gammill joined the foundation in 2020. Prior to her current role, she worked at the University of Washington (UW) as an Associate Professor in Obstetrics and Gynecology. After attending medical school at UW in Seattle, Washington, Dr. Gammill completed her Obstetrics and Gynecology residency and Maternal-Fetal Medicine fellowship at Magee-Womens Hospital in Pittsburgh, Pennsylvania. She then returned to Seattle and joined the UW faculty, where she initially worked in the multidisciplinary research group of Dr. J. Lee Nelson, a leader in the field of microchimerism research, at the Fred Hutchinson Cancer Research Center and then launched her own complementary research program at the UW. Dr. Gammill’s laboratory was part of the Center for Reproductive Sciences at UW’s dedicated research campus at South Lake Union. Her group focused on maternal-fetal exchange and immune interaction, and reproductive origins of maternal disease, with a particular emphasis on how material exchanged between mother and fetus during pregnancy can influence pregnancy outcomes and reflect placental status. In addition, her group investigated the durable persistence of cells exchanged between mother and fetus as microchimerism and their potential to influence later-life risk of and protection from diseases, for example in cardiovascular health after preeclampsia.
Dr. Moira Gunn is both an academic and a professional journalist. She is best known as the host of Tech Nation, and its regular segment BioTech Nation, on The NPR Channel on SiriusXM, other domestic and global networks, and numerous podcasting venues, including NPROne, Apple, Spotify, Pandora and Stitcher. Gunn interviews some 50 biotech CEO’s, global industry leaders, and research scientists each year, the total approaching 1,000 biotech interviews since the segment began. A broad range of topics are covered, from biopharmaceuticals to bioenergy, from AgBio to IndustrialBio, from biomedical devices to the networked digital healthcare of today. A former NASA computer scientist and engineer, she worked in satellite information systems, large scale modelling, and nutrition measurement before becoming a member of the faculty at the University of San Francisco. Today Professor Gunn is also the Director of Bioentrepreneurship, where her bioentrepreneurship courses are popular across the university to both science and non-science graduate students. Her book, “Welcome to Biotech Nation: My Unexpected Odyssey into the Land of Small Molecules, Big Ideas, and Lean Genes” was named to the Library Journal’s Annual Best Book List. The National Science Board awarded Gunn its Public Service Award to the Individual for her contributions to “Increasing the Public Understanding of Science and Engineering.” Following a Masters degree in Computer Science, Dr. Gunn went on to become the first woman to earn a PhD in Mechanical Engineering from Purdue University, where she was also awarded an honorary doctorate in Science.
Leslie Meltzer Henry is a lawyer and bioethicist with expertise in assessing, navigating, and advising on a range of ethical and legal issues that arise at the intersection of medicine, public health, and public policy. She is a Professor of Law at the University of Maryland Carey School of Law, and a faculty member at the Johns Hopkins Berman Institute of Bioethics. Her scholarly work primarily focuses on aspects of biomedical research regulation and practice that have implications for, and are implicated by, social justice and public health. Her scholarship has addressed barriers as well as potential facilitators to including women and pregnant people in research, compensation schemes for research-related injuries, challenges associated with including adolescents in research, and the complexities of conducting research during pandemics. She has been an investigator on both NIH and internationally funded grants aimed at developing ethically and legally acceptable strategies for conducting research during pregnancy, and she is currently an investigator on two NIH-supported studies – one examining the ethical, legal, and social implications (ELSI) of the increasingly blurred boundaries between infectious disease and genetics, and the second involving the use of HIV phylogenetics in clinical care and public health.
Professor Henry’s research has been published in the nation’s leading law reviews and medical journals, including JAMA, New England Journal of Medicine, PNAS, AIDS, Hastings Center Report, and Ethics and Human Research. She is an associate editor and contributor to the Oxford Handbook for Public Health Ethics (OUP, 2019), as well as a contributor to the Oxford Handbook of Research Ethics (OUP, 2020) and the Oxford Textbook of Clinical Research Ethics (OUP, 2008). Professor Henry has also served in an advisory capacity to a variety of federal and local agencies and commissions—including the U.S. Department of Defense, Trans-NIH Bioethics Advisory Committee, NIAID, NICHD, NIMH, and FDA—to identify limits, as well as areas of flexibility, in regulations related to the inclusion of special populations in research. Professor Henry received her J.D. from Yale Law School, Ph.D. from the University of Virginia, and M.Sc. from the University of Oxford, where she was a Wellcome Trust Fellow in the History of Medicine. She completed post-doctoral work at Johns Hopkins University as a Greenwall Fellow in Bioethics and Health Policy.
Carl V. Hill, Ph.D., MPH, is the chief diversity, equity and inclusion officer for the Alzheimer’s Association®, overseeing strategic initiatives to strengthen the Association’s outreach to all populations, and providing communities with resources and support to address the Alzheimer’s crisis.
Anula Jayasuriya is a successful private equity executive and venture capitalist whose background combines deep business, scientific and medical knowledge with broad clinical, industry, entrepreneurial, and investment experience as a private and as an institutional investor.
Integrating her passion with her investing expertise, in 2013 Anula founded EXXclaim Capital, an early-stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women’s Health. In 2006 Anula co-founded Evolvence India Life Science Fund, the first fund in India to focus exclusively on investing in India-based health care opportunities and the follow-on fund, India Life Science Fund II.
Previously, Anula was a partner with Skyline Ventures in Palo Alto; a principal with TVM in San Francisco; VP Business Development at Genomics Collaborative Inc.; and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation.
Anula received her BA from Harvard summa cum laude, and an MD and PhD in Microbiology and Molecular Genetics from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and earned an MBA with distinction from Harvard Business School. Anula also holds an MPhil in pharmacology from the University of Cambridge, in England.
Paula A. Johnson, President of Wellesley College, is an innovator recognized the world over for advancing, promoting, and defending women’s education, health, and well-being. This critically important work is deeply informed by her broad range of experience as a pathbreaking physician-scientist and educator who is an expert in health care, public health, and health policy. With a remarkable track record of accomplishments—including founding the Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital—she has led in the field of women’s health, taking an approach to biology that integrates insights from sociology, economics, and many other fields. A cardiologist, President Johnson was the Grayce A. Young Family Professor of Medicine in Women’s Health at Harvard Medical School and professor of epidemiology at the Harvard T.H. Chan School of Public Health. Her research—and the research, health care models, and training programs of the Connors Center—has had an impact on women across the country through its influence on health care and health policy reforms. Her work has also influenced and educated emerging leaders beyond the borders of the United States who are seeking to improve the health of women globally. Recently, President Johnson co-chaired the landmark report of the National Academies of Sciences, Engineering and Medicine, entitled Sexual Harassment of Women: Climate, Culture and Consequences in Academic Sciences, Engineering and Medicine. President Johnson is a member of the American Academy of Arts and Sciences and the National Academy of Medicine, the nation’s leading advisory organization providing expertise on issues relating to biomedical science, medicine, and health. She has been recognized as a national leader in medicine by the National Library of Medicine and has received several honorary degrees and numerous awards for her contributions to science, medicine, and public health. Most recently, she received the Stephen Smith Medal for Distinguished Contributions in Public Health by the New York Academy of Medicine. In her four years as president of Wellesley, she has advanced women’s higher education, championing cross-campus efforts to integrate the ideals of inclusive excellence into every aspect of academic and residential life. Under her leadership, the College is also developing new opportunities across all fields by drawing on the synergies found at the intersection of science, the humanities, and social sciences. Since last spring, President Johnson has served as a member of Governor Baker’s Higher Education Working Group and leads the Massachusetts Higher Education Testing Group that developed the framework for wide-scale COVID-19 testing for colleges and universities across the Commonwealth. President Johnson attended Harvard and Radcliffe colleges, received her A.B., M.D., and M.P.H. degrees from Harvard, and trained in internal medicine and cardiovascular medicine at Brigham and Women’s Hospital. A native of Brooklyn, New York, she and her husband are the parents of a son and a daughter.
P.K. earned her Medical Degree at the University of Texas Medical School at Houston, where she was a member of the Alpha Omega Alpha (AOA) Honor Medical Society. Subsequently, she completed her Internal Medicine Residency at Baylor College of Medicine and Hematology/Oncology Fellowship at the University of Texas MD Anderson Cancer Center, where she also served as a Chief Fellow. During her fellowship, she was named Fellow of the Year and earned the ASCO Young Investigator Award for her translational research in angiogenesis.Prior to joining Amgen, P.K. was an Assistant Professor, Department of Breast Medical Oncology, at the University of Texas MD Anderson Cancer Center. She co-led the development of the first multidisciplinary breast cancer survivorship clinic at MD Anderson and served as the principal investigator of multiple drug studies. From 2013 through 2015, as the Neupogen® /Neulasta® Global Development Lead and US Medical Lead, P.K. led a cross-functional team in the development and registration of the Neulasta® Onpro™. In addition, she led a pre-clinical and clinical team in the successful submission of the Neupogen® and Neulasta® Acute Radiation Syndrome (ARS) sBLAs, leading to approval of both products for the ARS indication. From 2014 to 2017, P.K. served as the Therapeutic Area Head for Oncology in the U.S. Medical Organization, where she oversaw U.S. oncology research activities, launch activities for newly approved oncology molecules, medical advocacy efforts, extramural research, and independent medical education grants. During this time, she successfully led the medical launch activities for IMLYGIC®, Kyprolis®, Neulasta Onpro™, and Blincyto®. In addition, P.K. served as the Global Product General Manager for three early-stage oncology molecules focused upon MCL-1 and KRAS G12C. Furthermore, P.K. was appointed by the FDA to be the industry representative to the Oncology Drug Advisory Committee (ODAC) for a four-year term, ending in 2019. In April 2019, P.K. became Vice President of Global Development and Therapeutic Area Head of Hematology, where she is responsible for guiding and accelerating late development activities addressing both marketed hematology programs (Blincyto and Kyprolis) and guiding the late development of programs that focus upon BCMA, FLT3, CD33, and MCL-1.
Claire Kinzy is the National Vice President of Women’s and Kids Health Initiatives on the consumer health team at the American Heart Association. In this role, she works enterprise-wide to identify, address and advance health priorities for both women and children. She has successfully worked to launch new initiatives such as Research Goes Red, a program designed to engage more women in the research process. Prior to returning to the American Heart Association in her current role, Claire spent nearly three years at The Cooper Institute in Dallas as the Vice President of Communications and Public Affairs, overseeing youth health programming, government relations and science communications. Born and raised in Dallas, Texas, Claire received a Master of Fine Arts in mass communications and a bachelor’s degree in biology from Texas Tech University.
Michael Lauer, M.D., is the Deputy Director for Extramural Research at the National Institutes of Health (NIH), where he serves as the principal scientific leader and advisor to the Director of the NIH on all matters relating to the substance, quality, and effectiveness of the NIH extramural research program and administration. He received education and training at Rensselaer Polytechnic Institute, Albany Medical College, Harvard Medical School, Harvard School of Public Health, and the NHLBI’s Framingham Heart Study. He spent 14 years at Cleveland Clinic as Professor of Medicine, Epidemiology, and Biostatistics. During his tenure at the Clinic, he led a federally funded internationally renowned clinical epidemiology program that applied big data from large-scale electronic health platforms to questions regarding the diagnosis and management of cardiovascular disease. From 2007 to 2015 he served as a Division Director at the National Heart, Lung, and Blood Institute (NHLBI), where promoted efforts to leverage big data infrastructure to enable high-efficiency population and clinical research and efforts to adopt a research funding culture that reflected data-driven policy. He has received numerous awards including the NIH Equal Employment Opportunity Award of the Year and the Arthur S. Flemming Award for Exceptional Federal Service in recognition of his efforts to grow a culture of learning and accountability.
Nathalie joined Nature Communications in 2019 and oversee the life and clinical sciences content published at the journal by a team of 60 editors. Nathalie was previously senior editor for stem cells and development at Nature Cell Biology for 8 years and Nature for 5 years. She is a member of Diversity, equity and inclusion working groups within the Nature portfolio. Nathalie has a keen interest for innovations and approaches aimed at increasing transparency in reporting in peer-reviewed articles to support research communities communicate their findings in a way that they can be used to advance science and help address the challenges faced by society. As an undergraduate, she studied molecular and cell biology at the ENS-Ulm in Paris, and joined the EMBL graduate programme in Heidelberg, Germany in 1995. Her post-doctoral research was carried out at the Gurdon Institute in Cambridge, UK and focused in studying early embryonic development using C. elegans as a model system.
Carolee Lee is an innovator, entrepreneur and thought leader dedicated to improving women’s health and wellbeing, and their opportunities to succeed. She was founder and CEO of Carolee Designs, one of the world’s leading accessories brands. After selling the company, Carolee focused her energies on women’s health and life planning. In 2008, she founded AccessCircles, a global, by-invitation network committed to bringing women access to leaders, resources and experiences that can help transform their lives. In 2018, Carolee launched Women’s Health Access Matters (WHAM!), a nonprofit organization to improve the health and wellbeing of women by accelerating attention to sex and gender in medical research, to better understand health conditions that occur exclusively or predominately in women in order to develop solutions that optimize women’s health. Carolee has forged a research partnership with the RAND Corporation to highlight the economic costs, benefits and social impacts of investing in health research that focuses on women, and is using that data to erase the gender research gap and accelerate women’s health around the world.Carolee is also a mentor and leader in business, philanthropic and educational organizations. She is a past Chair and Foundation Board Chair of the Committee of 200, a community of the most successful women in business, and has served as director on the board of DSW, Inc., a leading shoe retailer. Carolee is a founding board member of The Breast Cancer Research Foundation, where she has served since 1986. She currently sits on the Women’s Leadership Board at The John F. Kennedy School of Government at Harvard University.
Dr. Rachel L. Levine serves as the 17th Assistant Secretary for Health for the U.S. Department of Health and Human Services (HHS), after being nominated by President Joe Biden and confirmed by the U.S. Senate in 2021. As Assistant Secretary for Health, Dr. Rachel Levine fights every day to improve the health and well-being of all Americans. She’s working to help our nation overcome the COVID-19 pandemic and build a stronger foundation for a healthier future - one in which every American can attain their full health potential. After graduating from Harvard College and Tulane University School of Medicine, Dr. Levine completed her training in Pediatrics and Adolescent Medicine at the Mt. Sinai Medical Center in New York City. As a physician, she focused on the intersection between mental and physical health, often treating children, adolescents, and young adults. Dr. Levine was a Professor of Pediatrics and Psychiatry at the Penn State College of Medicine. Her previous posts included: Vice-Chair for Clinical Affairs for the Department of Pediatrics, and Chief of the Division of Adolescent Medicine and Eating Disorders at the Penn State Hershey Medical Center. In 2015, Pennsylvania Governor Tom Wolf nominated Dr. Levine to be Pennsylvania’s Physician General and she was subsequently unanimously confirmed by Pennsylvania’s state Senate. In 2017, Dr. Levine was named Acting Secretary of Health and confirmed to the position in March of 2018. During her time in state government, Dr. Levine worked to address Pennsylvania’s opioid crisis, focus attention on maternal health and improve immunization rates among children. Her decision to issue a standing order for the anti-overdose drug, Naloxone, saved thousands of lives by allowing law enforcement to carry the drug and Pennsylvanians to purchase it without a prescription from their doctor. Dr. Levine is a Fellow of the American Academy of Pediatrics, the Society for Adolescent Health and Medicine, and the Academy for Eating Disorders. She was also the President of the Association of State and Territorial Health Officials. In addition to her recent posts in medicine and government, Dr. Levine is an accomplished speaker and author of numerous publications on the opioid crisis, adolescent medicine, eating disorders, and LGBT medicine.
Jennifer Luray is the Senior Advisor at Research!America, the nation’s largest nonprofit alliance advocating for science, discovery, and innovation to achieve better health. She works across the organization to build partnerships and programs with academia, patient advocates, and industry. Prior to joining Research!America, Ms. Luray directed U.S. policy and government affairs for Fortune 500 lifescience companies, BD and Abbott. She partnered with internal and external stakeholders on public policy issues related to a range of drug, device and diagnostic technologies while advancing policy solutions to address medication safety, antibiotic stewardship and women’s health, among many other areas. Ms. Luray was Chief of Staff to former U.S. Senator Barbara Mikulski and Legislative Director to Congresswoman Nita Lowey. During the Clinton Administration, she was a Deputy Assistant to the President and Director of Women’s Initiatives and Outreach in the White House. Ms. Luray is a member of the Governing Committee of NESTcc, an FDA-funded initiative to research the use of real world data in medical device development. She is a member of the Advisory Board of the Brown University School of Public Health and the Stakeholder Advisory Board of the Johns Hopkins ALACRITY Center which supports mental health research. She currently chairs the Board of Directors of Planned Parenthood of Metropolitan Washington which serves 20,000 patients annually across the region. She received a B.A. in Sociology from Brown University and a Master in Public Administration from the Harvard Kennedy School of Government.
Ms. Masterson has a long career in venture capital investments and Board of Directors work. She sits on early stage company boards and public traded company boards. She coaches aspirational board candidates and is passionate about getting the DNA of the board right to support growth and success, financially for investors. As a lead investor in Portfolia FemTech Funds she supports women investors at the angel level to create and develop companies that women want to see from birth to menopause. She was a trailblazer for women in corporate sales management at Millipore and Ames Company and the first biotechnology analyst on Wall Street. As an entrepreneur she co-founded a DNA analysis company which was foundational to the genomics industry, called Sequenom. The company pioneered NIPT testing and went public in 2000. As an Adjunct Professor at University of San Francisco she teaches the business of biotechnology. She is the co-chair of the San Francisco chapter of Women Corporate Directors. She has been honored as an alumnae of achievement from Fordham University and is a published author and dynamic speaker. Her hobbies include horse-back riding and oil painting.
Dr. Maxwell is the Associate Dean for Research at Howard University College of Medicine. Dr. Maxwell is also currently serving as the Principal Investigator of The Center for Infectious Disease Management and Research (CIDMAR) Ryan White Part C and the Co-Principal Investigator for the HBCU Global Health Consortium (Zambia) and the CoVPN 3004 Covid-19 Vaccine Trial. She was formerly the Assistant Vice President for Health Sciences and the Principal Investigator of several prestigious projects in the past, including: The Henry J. Kaiser Family Foundation Barbara Jordan Congressional Scholars Program at Howard University; The Program to Combat Violent Crimes Against Women on Campuses; the Mid of -Atlantic AIDS Education and Training Center DC Local Performance Site at Howard University and the Center for Disease Control and Prevention-Comprehensive AIDS Training Initiative. Dr. Maxwell was selected by Sharon Pratt-Kelly, former Mayor of Washington, D.C. to co-chair the Transitional Task Force on AIDS services, and was also appointed to the Healthcare Reform Task Force chaired by First Lady, Hillary Rodman Clinton. Dr. Maxwell was appointed by Dr. Donna Shalala, then Secretary of Health and Human Services, and served on the Office of AIDS Research Advisory Council of the National Institutes of Health. Additionally, from 1994- 97, she served as a Special Assistant to the Commissioner of Food and Drugs, Dr. David Kessler. Dr. Maxwell was selected for the nationally renowned Robert Wood Johnson Health Policy Fellowship and through the fellowship, she served as a health legislative assistant for Senator Tom Harkin (D. Iowa). In 2015 she was inducted into the Washington DC. Hall of Fame and was appointed as a member of the Scientific Advisory Board, of the US President’s Emergency Plan for Aids Relief (PEPFAR) where she served until 2020. Dr. Maxwell obtained a Bachelor of Science in Nursing from Hunter College and her medical degree from Columbia University College of Physicians and Surgeons, both in New York. She completed her residency training in Internal Medicine at Howard University Hospital. Dr. Maxwell was also awarded a Fellowship in Parasitology at the National Institutes of Health, Laboratory of Parasitic Diseases. Her research interests involved the investigation of the immune response of humans to the hookworm parasite. Dr. Maxwell is also a Professor of Medicine in the Department of Medicine Division of Infectious Diseases. She is board certified in Internal Medicine and Infectious Diseases, and is a Fellow of the American College of Physicians, as well as a member of several boards and scientific associations. She gives numerous talks to professional and lay audiences and is a frequent guest on radio and television. Additionally, she lectures to diverse groups, including physicians, educators, students, national service organizations.
Dr. Leon McDougle's research interests include cross-cultural communication, especially as it relates to the patient physician relationship and its impact on healthcare outcomes of African Americans with diabetes, hypertension or chronic pain. In addition, he has identified opportunities to lead and promote partnerships that have led to externally funded research and training grants. For example, Dr. McDougle partnered with OSU College of Medicine biomedical scientist program leadership in submitting the National Institute of General Medical Sciences (NIGMS) R25 RFA to create a post baccalaureate program to enhance diversity of students entering PhD biomedical scientist training, DISCOVERY PREP. Dr. McDougle also serve as co-investigator for a NIMHD R01 funded research initiative led by Dr. Sakima Smith to determine the influence of CYP3A4*22 on simvastatin pharmacokinetics in African Americans to improve safety and decrease healthcare outcomes disparities. Leon McDougle, M.D., M.P.H., is the 1st African American Professor with tenure in The Ohio State University Department of Family Medicine and he’s the 1st Chief Diversity Officer ‘Aka Chief Collaborating Officer’ for the OSU Wexner Medical Center. A graduate of the University of Toledo and OSU College of Medicine, he completed the family medicine residency at the Naval Hospital Camp Pendleton, California, and earned a Master of Public Health degree from the University of Michigan School of Public Health, Department of Health Management and Policy. Dr. McDougle was recognized as being among the top 10 percent of physicians nationally for patient satisfaction. Dr. McDougle was installed as the 121st President of the National Medical Association on August 4, 2020 during the 125th Anniversary of the NMA. Dr. McDougle is a past Chair for the Association of American Medical Colleges (AAMC) Group on Diversity and Inclusion. He has provided service for the AAMC as faculty for the Healthcare Executive Diversity and Inclusion Certificate Program, Minority Faculty Leadership Seminar, and Mid-Career Minority Faculty Leadership Seminar. In addition, he directs several workforce diversity programs including the MEDPATH Post-baccalaureate Program. He is a Diplomate of the American Board of Family Medicine and Fellow of the American Academy of Family Physicians. Dr. McDougle is a member of the Rhema Christian Center. He is a member of the Association of Military Surgeons of the United States and the Alpha Omega Alpha Honor Medical Society. A native of Sandusky, Ohio, Leon and his wife, Natasha Jones-McDougle, M.Ed. are the proud parents of Peri and Autumn.
Michelle McMurry-Heath, BIO President & CEO Michelle McMurry-Heath assumed the leadership of the Biotechnology Innovation Organization (BIO) as President and CEO on June 1, 2020. A medical doctor and molecular immunologist by training, Dr. McMurry-Heath becomes just the third chief executive to steward the world’s largest biotechnology advocacy group since BIO’s founding in 1993. BIO represents 1,000 life sciences companies and organizations from 30 countries. The organization’s mission is to discover and deploy scientific breakthroughs that improve human heath, environmental stewardship, and sustainable agriculture. The common thread in McMurry-Heath’s work across academia, government and industry has been her focus on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge innovation. Driven by her own past family experiences navigating clinical trials and funding uncertainties within the rare disease community, McMurry-Heath calls “the distribution of scientific progress the social justice issue of our age.” She comes to BIO from Johnson & Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. She was also instrumental in bringing J&J’s incubator, JLabs, to Washington, DC. She led a global team of 900 with responsibilities in 150 countries around the globe. Prior to her time at J&J, Dr. McMurry-Heath was also a key science policy leader in government. The Obama-Biden transition team tapped her to conduct a comprehensive analysis of the National Science Foundation’s policies, programs and personnel. President Obama then named her associate science director of the FDA’s Center for Devices and Radiological Health under Commissioner Peggy Hamburg. In that role, she championed clinical trial evolution, the use of real-world evidence in product evaluation, and an embrace of the patient’s voice in health research so new medical products deliver outcomes that matter to them. McMurry-Heath was the founding director of the Aspen Institute’s Health, Biomedical Science, and Society Policy Program, where she promoted personalized medicine and bolstered international preparation for pandemic disease threats. She received her early training in science policy from the Robert Wood Johnson Foundation and later served as Senator Joe Lieberman’s top legislative aide for science and health. In that role, she drafted legislation to protect the country from biological attacks. McMurry-Heath received her MD/PhD from Duke’s Medical Scientist Training Program, becoming the first African-American to graduate from the prestigious program. She spent 12 years working at the research bench before taking policy and leadership roles in government and industry. McMurry-Heath lives in Washington, D.C. with her husband Sebastian Heath, a veterinarian, and their daughter, Isabella. To relax, she enjoys yoga, snorkeling and her daughter’s sporting events.
Jessica Miles, PhD, is a Senior Publisher at Cell Press. She manages 22 journals, including the Trends reviews journals and several society titles, and leads a team of 16 PhD-trained Editors to execute strategy across the portfolio and support innovation across Cell Press. She also co-chairs Elsevier's forum for Sex- and Gender-based Analysis in Research. Previously, Dr. Miles directed the high-profile Cell Symposia conference series and worked in the legal sector prior to joining Elsevier/Cell Press. She holds a doctorate in Microbiology from Yale University.
Erika Miller, JD serves as Senior Vice President and Counsel at CRD Associates. Through her career, she has developed broad experience in government relations representing a range non- profit organizations ranging from medical specialty societies, coalitions, and patient advocacy organizations, including a number engaged on women’s health issues. Erika has expertise in the intricacies of Medicare policy and provides guidance to clients as they navigate the evolving area of health care payment and quality. Erika is a co-author of a chapter entitled, “Lobbying the Appropriations Process” in the American Bar Association Lobbying Manual. A New Jersey native, Erika worked in the office of Congressman Steve Rothman of New Jersey where she handled immigration issues. Erika also worked in the U.S. Department of Health and Human Services Office on Women's Health, where she monitored grant awards. Prior to joining CRD Associates in 2005, Erika worked at the lobbying firm of Broydrick & Associates representing health care interests. She served as co-chair of the Women in Government Relations Health & Social Polices Task Force and is member of the group Women Business Leaders in Health Care. Erika received her law degree from The American University, where she was an editor of the Administrative Law Review. She earned an undergraduate degree in Political Science from Colgate University.
Dr. Alondra Nelson currently serves at the inaugural Deputy Director for Science and Society in the White House Office of Science and Technology Policy. In this role, she brings social science expertise, including attention to issues of social inequality, explicitly into the work of Federal science and technology strategy and policy.
Dr. Nelson is also Harold F. Linder Chair and Professor at the Institute for Advanced Study, an independent research center in Princeton, NJ. She was president of the Social Science Research Council, an international research nonprofit from 2017-2021. She was previously professor of sociology at Columbia University, where she also served as the inaugural Dean of Social Science. Dr. Nelson began her academic career on the faculty of Yale University and there was recognized with the Poorvu Prize for interdisciplinary teaching excellence.
Dr. Nelson’s major research contributions are situated at the intersection of political and social citizenship, on the one hand, and emerging scientific, medical, and technological phenomena, on the other. Her work explores science, medicine, and technology as sites of both risk and empowerment, especially for underserved and vulnerable communities. Dr. Nelson connects these dimensions in a range of widely acclaimed and award-winning publications, including Technicolor: Race, Technology, and Everyday Life (with Thuy Linh N. Tu); Genetics and the Unsettled Past (with Keith Wailoo and Catherine Lee); Body and Soul: The Black Panther Party and the Fight Against Medical Discrimination; and The Social Life of DNA.
Dr. Nelson is a member of the American Academy of Arts and Sciences, the American Academy of Political and Social Science, the American Philosophical Society, and the National Academy of Medicine.
Charlotte D. Owens, M.D., FACOG, is the Therapeutic Area Lead in U.S. Medical Affairs for Women’s Health at AbbVie, and oversees the therapeutic area’s scientific communications, educational efforts and publications. Prior taking on her current role at AbbVie, Dr. Owens was responsible for helping lead the direction, planning, execution, and interpretation of clinical trials to deliver high-quality clinical data at AbbVie, with a focus on women’s health as a Medical Director in Clinical Development. In this role, she led clinical research to identify a new treatment option for symptomatic uterine fibroids that successfully enrolled and retained nearly 800 women, roughly two-thirds of whom were African American women – a group that is typically underrepresented in research but disproportionally impacted by this disease. Immediately prior to joining AbbVie, Dr. Owens was an Assistant Clinical Professor of Obstetrics and Gynecology, Director Division of Industry Collaborative Research and Chief Medical Officer for the Office of Translational Technologies at the Morehouse School of Medicine. Throughout her diverse career, Dr. Owens has also worked in medical device research and development, television news as a medical expert, and strategic healthcare consulting with expertise in multiple therapeutic areas. In addition to her responsibilities at AbbVie, she is a practicing board-certified obstetrician and gynecologist and Adjunct Clinical Assistant Professor at the Morehouse School of Medicine. Dr. Owens received her B.S. in physiology from the University of California Davis, and her M.D. from the University of Michigan Medical School.
"Sudip Parikh, Ph.D., became the 19th chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals in January 2020. Parikh has spent two decades at the nexus of science, policy, and business.
Immediately prior to joining AAAS, Parikh was senior vice president and managing director at DIA Global, a neutral, multidisciplinary organization bringing together regulators, industry, academia, patients, and other stakeholders interested in healthcare product development. He led strategy in the Americas and oversaw DIA programs that catalyzed progress globally toward novel regulatory frameworks for advanced therapies not amenable to existing regulations. Prior to DIA, Sudip was general manager of the Health and Consumer Solutions business unit and vice president at Battelle, a multibillion-dollar research and development organization. He led a $150 million business unit with over 500 scientific, technical, and computing experts performing basic and applied research, developing medicines and healthcare devices, and creating advanced analytics and artificial intelligence applications to improve human health. Previously, Parikh led Battelle’s global AgriFood business unit. Headquartered in London and Geneva, this unit provided environmental fate research and agriculture product development services from laboratories throughout Europe and the United States. From 2001 to 2009, Parikh served as science advisor and professional staff to the United States Senate Appropriations Committee, where he was responsible for negotiating budgets for the National Institutes of Health (NIH), Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, Biomedical Advanced Research and Development Authority, and other scientific and health agencies. A key legislative liaison to the research and development ecosystem, Parikh was on the frontlines of many science policy issues debated during that time, including embryonic stem cell research, cloning, disease surveillance, bioterrorism, cyber security, and doubling the NIH budget. An active member of the scientific advocacy community, Parikh serves as a board member and officer for several impactful organizations, including Research!America, Friends of Cancer Research, and ACT for NIH. He has received multiple public service awards, including recognition from the American Association of Immunologists, the National AIDS Alliance, the Coalition for Health Services Research, and the Juvenile Diabetes Research Foundation. Sudip is committed to early STEM education and, as a parent of three energetic young children, he prioritizes volunteering as a mentor for Science Olympiad teams at two elementary schools. Early in his career, Parikh was a Presidential Management Intern at the NIH. He was awarded a National Science Foundation Graduate Research Fellowship while earning his Ph.D. in macromolecular structure and chemistry from the Scripps Research Institute in La Jolla, Calif. There, he used structural biology and biochemistry techniques to probe the mechanisms of DNA repair enzymes bound to DNA. The son of Indian immigrants who worked in the textile and furniture manufacturing plants of North Carolina, Parikh completed undergraduate studies at the University of North Carolina at Chapel Hill, first as a journalism major before switching into materials science."
Gemima Philippe is a communication associate for the American Association for the Advancement of Science Center for Public Engagement with Science and Technology. She coordinates marketing and social media for Center programs, facilitates Communicating Science workshops, and supports other Center programs. Prior to joining AAAS in 2016, Gemima worked with both federal and private sector clients to promote occupational health and health communication services and with volunteer organizations to promote adolescent health.
Vivian W. Pinn, MD was the first full time director of the NIH Office of Research on Women’s Health from 1991 and Associate Director of NIH for Women’s Health Research from 1994 until her retirement in 2011 when she was named Senior Scientist Emerita at the NIH Fogarty International Center. Under her leadership, the new office led the implementation of NIH inclusion policies for women and minorities in clinical research, developed the first and several subsequent strategic plans for women’s health research, and established new research initiatives and career development programs in collaboration with NIH Institutes and Centers. She established and co-chaired the NIH Working Group on Women in Biomedical Careers with the NIH Director. Prior to NIH she was Professor and Chair of the Department of Pathology at Howard University and previously held teaching appointments at Harvard and Tufts Universities. A graduate and former Alumna Trustee of Wellesley College, she earned her M.D. in 1967 from the University of Virginia School of Medicine, the only woman or minority in her class. She received her post-graduate training in Pathology as an NIH Research Fellow at the Massachusetts General Hospital. Dr. Pinn is a fellow of the American Academy of Arts and Sciences and was elected to the National Academy of Medicine in 1995. She served several terms on the National Academies Committee on Women in Science, Engineering and Medicine and was a member of the National Academies committee that prepared the 2020 report on ‘Promising Practices for Addressing the Underrepresentation of Women in Science, Engineering, and Medicine: Opening Doors’. She is also a member of the National Academies Roundtable on Black Men and Black Women in Science, Engineering, and Medicine. Dr. Pinn currently serves on the Board of Trustees/Advisors of Thomas Jefferson University, the Sidney Kimmel Cancer Center at Jefferson, Tufts University School of Medicine and the KGI School of Medicine, and holds the position of Professor, Institute for Advanced Discovery & Innovation at the University of South Florida. Dr. Pinn has received innumerable honors, including 17 Honorary Degrees of Science, Law and Medicine. The University of Virginia (UVA) School of Medicine named one of its four advisory medical student colleges as ‘The Pinn College’. Tufts University School of Medicine in 2011 announced the ‘The Vivian W. Pinn Office of Student Affairs’, at the time her former medical students dedicated a scholarship in her name. In 2016, UVA announced that the medical research and education building was renamed for her as “Pinn Hall.” And in December 2016, UVA medical school also announced the inaugural Pinn Scholars program to support and recognize mid-level faculty in efforts to take their research in novel directions. She has held leadership positions in many professional organizations, including as the 88th President of the National Medical Association (NMA) and is currently Chair of the NMA Past Presidents Council. Among other recent honors, she received the 2020 American Medical Association’s Distinguished Service Award for her leadership in women’s health as well as the 2020 Alma Dea Morani Award from the Women in Medicine Legacy Foundation and the New York Academy of Medicine.
Londa Schiebinger is the John L. Hinds Professor of History of Science at Stanford University, and Founding Director of Gendered Innovations in Science, Health & Medicine, Engineering, and Environment. Gendered Innovations harnesses the creative power of sex, gender, and intersectional analysis to enhance excellence and reproducibility in science. She is a leading international expert on gender in science and technology and has addressed the United Nations, the European Parliament, the Korean National Assembly, and numerous funding agencies on that topic. Schiebinger received her Ph.D. from Harvard University and is an elected member of the American Academy of Arts and Sciences. She is the recipient of numerous prizes and awards, including the prestigious Alexander von Humboldt Research Prize and Guggenheim Fellowship. From 2018-2020, she directed a European Commission expert group to produce: Gendered Innovations 2: How Inclusive Analysis Contributes to Research and Innovation. From 2011-2012 she directed a European Commission expert group to produce: Gendered Innovations: How Gender Analysis Contributes to Research. Recent publications include: AI can be Sexist and Racist—It’s Time to Make it Fair Nature (2018); Sex and Gender Analysis Improves Science and Engineering Nature (2019); Analysing How Sex and Gender Interact The Lancet (2020); Gender-Related Variables for Health Research The Biology of Sex Differences (2021). For late-breaking news on Gendered Innovations, sign up here. Follow us on Twitter @GenderInnovate. Her books include: The Secret Cures of Slaves: People, Plants, and Medicine in the 18th Century Atlantic World; The Mind Has No Sex? Women in the Origins of Modern Science; the prize-winning Nature’s Body: Gender in the Making of Modern Science; and Has Feminism Changed Science? She was awarded the 2005 Prize in Atlantic History from the American Historical Association and the 2005 Alf Andrew Heggoy Book Prize from the French Colonial Historical Society for her Plants and Empire: Colonial Bioprospecting in the Atlantic World. She also won the 2005 J. Worth Estes Prize from the American Association for the History of Medicine for an article of outstanding scholarly merit in the history of pharmacology. Her work has been translated into thirteen languages. Londa Schiebinger holds Honorary Doctorates from the University of Valencia, Spain, the Faculty of Science, Lund University, Sweden, and the Vrije Universiteit Brussel and is a Distinguished Affiliated Professor at the Technische Universität, Münichen. She has also served as a Senior Research Fellow at the Max-Planck-Institut für Wissenschaftsgeschichte in Berlin, the Jantine Tammes Chair in the Faculty of Mathematics and Natural Sciences at the University of Groningen, a guest professor at Princeton, Göttingen, and Oldenburg.
Kathryn G. Schubert (Katie) is President and CEO of the Society for Women’s Health Research (SWHR), where she leads the organization’s efforts to promote research on sex as a biological variable and improve women’s health through science, policy and education. Prior to joining SWHR in April of 2020, Katie served as Chief Advocacy Officer at the Society for Maternal-Fetal Medicine (SMFM), where she oversaw the organization’s advocacy and communications activities. Prior to joining SMFM, she was a Senior Vice President at CRD Associates. Her clients included patient advocacy organizations, physician organizations and coalitions, helping them achieve their public policy and communications goals through focused government relations strategy targeted at Congress and federal agencies. Her areas of expertise include Medicare and Medicaid reimbursement and quality, women’s and children’s health and public health. Katie previously served in key staff roles for U.S. Representative Nancy Johnson (R-CT) and Wayne Gilchrest (R-MD), and brings a unique perspective of working across party lines to achieve policy goals. She currently serves as Chair of the Board of the Maternal Mental Health Leadership Alliance and as an advisor to the John E. Lewy Fund for Children’s Health. She is a past president of Women in Government Relations (WGR), the premier professional association for women in the government relations profession. She holds a Master of Public Policy degree with a concentration in health policy from The George Washington University and attended Mary Washington College in Fredericksburg, Virginia, where she earned a B.A. in Political Science. She lives in Virginia with her husband, three children, and dog George.
Karla Shepard Rubinger is Vice President at Mary Ann Liebert Inc. (www.liebertpub.com), and Executive Director of the Institute for Professional Education (www.instituteforprofessionaled.org). At Mary Ann Liebert Inc., she was instrumental in the launch of peer-reviewed journals such as, Breastfeeding Medicine, Sustainability and Climate Change, Violence and Gender and Health Equity, all indexed in Medline, and available in print and online. The core publications of Mary Ann Liebert Inc. include 100 peer-reviewed biomedical journals as well as several law-related journals including Biotechnology Law Report, and Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science. Our Institute for Professional Education, in concert with the Journal on Women’s Health, hosted the annual Congress on Women’s Health for 25 years. Several of the journals with particular current policy relevance are: Health Security, Telemedicine and e-Health, AIDS Patient Care and STDs, AIDS Research and Human Retroviruses, and LGBT Heath. In support of a long-standing commitment to the careers of women and under-represented minorities in science, she is also the Executive Director of the Rosalind Franklin Society. With a prestigious board of men and women, including 5 Nobel Laureates, the mission is to promote more tenure track positions, awards, and recognition worldwide. The most recent end-of-year conference Labs, Leaders, Critical Connections, attracted over 1,200 registrations. With an extensive background in foundations and philanthropy, she has worked to develop partnerships with funders to significantly expand the reach of these important projects and publications. She has served on Advisory Committees for the Robert Wood Johnson Foundation and was previously Senior Program Officer of The Commonwealth Fund, Director of Research for the Juvenile Diabetes Foundation International, Executive Director of the Ennis William Cosby Foundation, and Research Associate at the Institute for Research in Human Development at Educational Testing Service in Princeton. Her graduate work includes an M.Sc. from the London School of Economics and the Ph.D. program at Princeton University.
Judith Steinberg is the Chief Medical Officer (CMO) of the Department of Health and Human Services Office of Infectious Disease and HIV/AIDS Policy (OIDP). This Office, which is part of the Office of the Assistant Secretary for Health, coordinates the Ending the HIV Epidemic: A Plan for America initiative and the development and implementation of our national strategic plans for HIV, viral hepatitis, sexually transmitted infections, vaccines and vector-borne diseases. As the CMO, Dr. Steinberg serves as a senior subject matter expert, providing medical and scientific expert advice and counsel across the broad infectious disease portfolio of the Office. Dr. Steinberg serves on the Advisory Committee for Immunization Practices COVID-19 vaccine safety technical subgroup. She also served as the safety CMO for the US Public Health Service Commissioned Corps Command Center that oversees and steers the COVID 19 deployments of our public health officers.
Prior to joining the OIDP, Dr. Steinberg was the CMO of the Bureau of Primary Health Care (BPHC), part of the Health Resources and Services Administration, which funds and administers the health center program. Dr. Steinberg was an associate professor of medicine at the University of Massachusetts (UMass) Medical School and an assistant professor of medicine at Boston University School of Medicine. She has more than 25 years of experience in primary care and infectious disease, including caring for patients at community health centers and safety net hospitals in Massachusetts. At UMass Medical School, she provided clinical expertise and leadership in the design and implementation of new healthcare delivery and value-based payment models.
Dr. Steinberg earned her medical degree from the University of Texas, and completed a residency in internal medicine at Beth Israel Hospital in Boston, as well as an infectious disease fellowship at Beth Israel/Brigham and Women’s Hospitals in Boston. She was a Commonwealth Fund/Harvard University fellow in minority health policy and received a master’s degree in public health from Harvard University.
Janet Stovall is a Senior Client Strategist at NeuroLeadership Institute (NLI). In her role at NLI, Janet helps organizations replace subjectivity with science to evolve diversity, equity and inclusion practices to be more brain-friendly, more human—and more effective.
Janet’s career evolved from a technical systems analyst role at Morgan Stanley into various corporate and agency marketing and public relations roles, including founding her own firm. Her most recent position was speechwriter for the CEO and senior leadership of UPS, one of the world’s largest shipping and logistics companies, with more than 500,000 employees globally. She is one the few Black speechwriters to have worked at the C-level in the Fortune 500.
Janet also led UPS’s diversity, equity and inclusion communications, writing and producing an award-winning video, The Power of Difference, writing award-winning executive speeches, and serving as a founding member of the UPS Equity, Justice & Action Task Force. She developed the task force’s mission and vision statements, established the company’s framework for action to address racial inequity, and authored the group’s first-year accomplishments report and recommendations. Janet also served as Senior Director, Social Impact and The UPS Foundation, working to advance UPS’s global philanthropy, social impact and community engagement efforts. Her TED talk challenging business to get serious about inclusion has nearly 2 million views.
Janet holds a bachelor’s degree in English from Davidson College, a master’s degree in Integrated Marketing Communications from Georgetown University, and post-graduate certificates in Diversity and Inclusion from Cornell University and Yale University.
Kim Templeton, MD is Professor of orthopaedic surgery at the University of Kansas Medical Center in Kansas City and department vice-chair for diversity and equity. She was the first McCann Professor of Women in Medicine and Science in the United States. She received the inaugural Women Leaders in Medicine Award from the American Medical Student Association in 2008, the Marjorie J. Siddridge leadership award for women in medicine from the University of Kansas in 2012, the AMWA Elizabeth Blackwell Award for outstanding contributions to the cause of women in the field of medicine in 2013, and the AMWA Bertha Van Hoosen Award in 2019 for exception leadership and service to women physicians and students. She was named to the University of Kansas Women’s Hall of Fame and an honorary alumnus of the University of Kansas in 2014. Dr. Templeton is a past-president of the American Medical Women’s Association. During her tenure as president of AMWA, Dr. Templeton developed the organization’s Wellness Initiative and continues to lead that. Dr. Templeton is also co-chair of the AMWA Opioid Addiction in Women Task Force. Dr. Templeton is past vice-chair of the AMA Women Physician Section and past chair of the AMA Orthopaedic Section. She initiated and worked with the AMA in developing their new policy that recognizes an “expanded definition of ‘women’s health”. Dr. Templeton is a member of the NBME and participates on the RENEW task force and is a representative to the AAMC Council on Faculty and Academic Societies. She is a member of committees within the NQF and the bone and joint expert review committee of the NCQA. Dr. Templeton is a past president of the US Bone and Joint Initiative. During her tenure as president of the USBJI, she developed multiple public education programs to address the burden of musculoskeletal conditions. Dr. Templeton is past-president and a current member of the Kansas State Board of Healing Arts. During her tenure as president of the KSBHA, she helped develop a new category of “re-entry license”, one of the few such in the US. In 2019, Dr. Templeton worked with the Board to change licensure language to no long ask about specific applicant/licensee health issues, to encourage those in healthcare to seek the care that they need. Dr. Templeton is a member of the Kansas prescription drug monitoring program advisory committee and the HealthyWomen chronic pain task force. Dr. Templeton’s publications focus on issues faced by women physicians and the inclusion of sex and gender constructs in medicine and health professionals’ education. Her work addressing the issues of women physicians extends from medical students to those nearing the end of practice and includes such topics as burnout and re-entry to practice. Dr. Templeton was the lead author on the National Academy of Medicine paper on burnout among women physicians that came out in 2019 and the senior author of a paper published in 2020 that was the first to address issues faced by senior women physicians.
Dr. Jane van Dis is an OB Hospitalist with OB Hospitalist Group, and soon to be Assistant Faculty in the Department of ObGyn at the University of Rochester. She is currently Medical Director at MavenClinic, Co-Founder of Equity Quotient and Equity Metric, equity solutions for healthcare. Dr. van Dis is also Co-Founder of Ob Best Practice which advises OBG Project, an online resource for ObGyns and learners. She is a Co-Founder of TIMESUP Healthcare. She lectures frequently on gender and equity in healthcare and has published on the topic in Slate, the New England Journal of Medicine and Harvard Business Review. In addition, Dr. van Dis advises multiple health care startups and is a Lead Investor at Portfolia. She is a single mom to twins, Brooklyn and Miles.
Dr. Kaveeta Vasisht is Associate Commissioner for Women’s Health and serves as the Director of the Office of Women’s Health (OWH) in the Office of the Commissioner of the US Food and Drug Administration (FDA). In this capacity she serves as the principal advisor to the Commissioner and other key Agency officials on scientific, ethical, and policy issues relating to women's health. In addition to promoting the inclusion of women in clinical trials and the completion of sex/gender analysis, OWH monitors the progress of crosscutting and multidisciplinary women's health initiatives including areas that require study and new challenges to the health of women as they relate to FDA's mission. Under her leadership, OWH works to protect and advance the health of women through scientific programs, policy development, research, education, stakeholder collaboration, and outreach that incorporate an understanding of sex and gender differences to facilitate FDA regulatory decision making. In addition to directing OWH, Dr. Vasisht represents FDA on various cross Agency expert committees focused on the health of women, including the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC). Prior to joining the Office of Women’s Health, Dr. Vasisht served as the Deputy Director for the Division of Clinical Trial Quality in the Office of Medical Policy in the Center for Drug Evaluation and Research. Dr. Vasisht began her career at the FDA in the Division of Metabolism and Endocrine Products, Office of New Drugs, where she served as the clinical expert on multidisciplinary teams in the review and evaluation of scientific data to make regulatory decisions regarding risk-benefit assessments on the safety and effectiveness of therapeutics for the U.S. population.
Dr. Vasisht is board-certified in both internal medicine and adult endocrinology and holds a Doctor of Pharmacy degree. She completed her internal medicine and fellowship training at the University of Chicago Hospitals, where she also served on the faculty. She obtained her medical degree from the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School.
Dr. Yesmean Wahdan, MD is a Senior Medical Director for US Medical Affairs in the Bayer Women’s HealthCare division. She received her Bachelor’s Degree in Cellular and Molecular Biology from Marymount University and her Medical Degree from Georgetown University School of Medicine. She completed her OB/GYN residency at combined program at Georgetown University Medical Center and Washington Hospital Center in Washington, DC. She has also published a number of abstracts and articles in the American Journal of Obstetrics and Gynecology and the Journal of Reproductive Science.
Dr. Janice Werbinski is a staunch advocate for medical education that must change the way healthcare is delivered to women, taking into consideration the many ways in which their health, physiology, and needs differ from men’s. She is President of the American Medical Women’s Association for 2021-2. She was also presented with the 2020 AMWA Lila A. Wallis Women’s Health Award, reflecting “lifetime achievements…in women’s health, education, and research.” From 2009-2020, she served as Executive Director of AMWA’s Sex and Gender Health Collaborative, designed to inform students, faculty, and clinicians in sex and gender-appropriate medicine, with the goal of improving the health and healthcare of women. Currently, as Clinical Associate Professor Emerita at Western Michigan University Homer R. Stryker MD School of Medicine, she teaches Sex and Gender Specific Medicine, and has written an iBook on that topic. She has published numerous peer reviewed articles on Women’s Health and Sex Specific Medicine and contributed content and chapters to textbooks on the topic. She received her Magna Cum Laude Bachelor’s Degree at Western Michigan University in 1969, MD Degree from the Medical College of Wisconsin in 1975. Board-certified in OB GYN, and a Certified Menopause Provider, she practiced Women's Health and Gynecology in Kalamazoo for 40 years, retiring from clinical practice in 2014. During her career in Kalamazoo, she was Medical Director of both Bronson’s Center for Women’s Health (1988-1996) and Borgess Women’s Health (1996-2013). For 15 years, she served as volunteer Founding Medical Director of the Kalamazoo YWCA Sexual Assault Nurse Examiner (SANE) program, and she was instrumental in creating the woman-friendly discreet examination area there.
Susan F. Wood is Research Professor of Health Policy and Management at the George Washington University Milken Institute School of Public Health. She is also the Director of the Jacobs Institute of Women’s Health, which publishes the peer reviewed journal, Women’s Health Issues. Prof Wood’s work and public advocacy focuses on women’s health and the use of scientific knowledge in public policy.
She previously was Assistant Commissioner for Women’s Health at the FDA, and directed the FDA Office of Women’s Health from 2000-2005, when she resigned due to the continued delay of approval of emergency contraception as an over-the-counter product. Prior to her time at FDA, Dr. Wood was Director of Policy and Program Development at the US Dept of Health and Human Services’ Office on Women’s Health.
From 1990-1995, Dr. Wood worked on Capitol Hill as professional staff for the Congressional Caucus for Women’s Issues Initially as Science Advisor and later as Deputy Director to the Caucus, Dr. Wood helped develop and promote the Women’s Health Equity Act, and was directly involved with many policy initiatives and legislative proposals which would advance biomedical research, women’s health, family planning, and health care reform.
Previously, Dr. Wood was a research scientist at John Hopkins University School of Medicine; she received her PhD in biology from Boston University. She has published a number of research articles in scientific journals, as well as articles on health policy. She has received numerous awards for her work including the Keystone Award in Women’s Health Research from the NIH Office of Research on Women’s Health.
Dr. Yano is Director of the VA HSR&D Center for the Study of Healthcare Innovation, Implementation, & Policy at the VA Greater Los Angeles Healthcare System and Adjunct Professor of Health Policy & Management at the UCLA Fielding School of Public Health and of Medicine at the UCLA Geffen School of Medicine. With over 30 years of experience, Dr. Yano’s primary research expertise is in evaluating impacts of primary care and women’s health care delivery models and testing evidence-based quality improvement approaches for implementing and/or tailoring care models to improve quality, patient experience, and health outcomes. She has had a central role in building VA’s women’s health research capacity, leading development of VA’s women’s health research agenda and directing the VA Women’s Health Research Network (WHRN) (2010-present), for which she leads a national Consortium of researchers to accelerate research development. Dr. Yano also co-leads the VA Women’s Health Practice Based Research Network, comprised of 73 VA medical centers and over 300 community-based outpatient clinics to foster inclusion of women Veterans in VA research. She has advanced multilevel stakeholder engagement methods to foster implementation and spread of research evidence through collaborative networks on the frontlines of care while her research has had measurable impacts on evidence-based practice and policy. WHRN has since served as a model for building widespread research collaboratives capable of accelerating research impacts on Veterans’ care in areas of chronic pain/opioids, access, virtual care, and suicide prevention. She also leads the Implementation & Training Core of the Coordinating Hub to Promote Research Optimizing Veteran-Centric Electronic Health Record (EHR) Networks (PROVEN), which seeks to accelerate EHR-related research with VA’s implementation of a new $16 billion EHR. She also leads a secondary analysis study capitalizing on inclusion of Veteran and VA-user status in National Health Interview Survey and other data enabling comparisons and contrasts in disease burden and utilization among Veteran VA users, non-users and civilians, with a focus on health equity. Dr. Yano co-directs the VA Advanced Fellowship in Women’s Health and serves as faculty mentor for an array of early and mid-career researchers focused on women’s health, primary care, and partnered research driving Learning Healthcare Systems toward improved performance. She is on the Board of Directors for AcademyHealth, the nation’s premier health services research and health policy professional organization, dedicated to moving evidence into action, and has provided expert scientific review for NIH, AHRQ, PCORI, and VA and delivered numerous Congressional briefings and testimony on women Veterans’ health research. She has received the VA HSR&D Senior Research Career Scientist Award, the VA Under Secretary for Health Award for Outstanding Accomplishment in Health Services Research, the Breslow Lifetime Achievement Award for the UCLA Fielding School of Public Health Alumni Hall of Fame, and a Special Recognition Award from Disabled American Veterans for her research impacts on women Veterans’ care, and was named one of 50 Women of Impact in U.S. Health Care. She has published over 250 papers and delivered over 500 scientific presentations.
Julie M. Zissimopoulos is Associate Professor in the Sol Price School of Public Policy at the University of Southern California. In addition to her faculty appointment, she serves as Director of Aging and Cognition Research Program and Research Training at the Schaeffer Center for Health Policy and Economics. She is Director of USC’s Resource Center for Minority Aging Research, and Center for Advancing Sociodemographic and Economic Study of Alzheimer’s Disease and Related Dementias (CeASES-ADRD), both focused on reducing burden of Alzheimer’s disease and funded by the National Institute on Aging (NIA). Dr. Zissimopoulos is currently leading several NIA funded research projects on: the health of caregivers for persons with dementia; the use of and response to drug therapies for non-Alzheimer’s disease and related dementia conditions that influence risk of dementia; racial and ethnic disparities in diagnosis and health care treatment for dementia; and measuring incidence and prevalence of dementia using Medicare claims and survey data. Her recently published research appears in numerous publications such as the Journal of the American Medical Association Neurology, Journal of Gerontology Social Science, Journal of the American Academy of Arts and Sciences, Journal of Health Economics and Alzheimer’s and Dementia. Her research on the economics of aging is disseminated through media outlets such as the New York Times, Washington Post, Los Angeles Times, CNN, National Public Radio. Dr. Zissimopoulos received her B.A. summa cum laude from Boston College, her M.A. from Columbia University, and a Ph.D. in economics from the University of California, Los Angeles.
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events